Cover Image

CT-guided high-dose-rate brachytherapy versus transarterial chemoembolization in patients with unresectable hepatocellular carcinoma

Background - - CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce. - - Purpose - - To c...

Full description

Saved in:
Bibliographic Details
Main Authors: Auer, Timo Alexander (Author) , Müller, Lukas (Author) , Schulze, Daniel (Author) , Anhamm, Melina (Author) , Bettinger, Dominik (Author) , Wagner, Verena (Author) , Haubold, Johannes (Author) , Zopfs, David (Author) , Pinto dos Santos, Daniel (Author) , Eisenblätter, Michel (Author) , Gebauer, Bernhard (Author) , Kloeckner, Roman (Author) , Collettini, Federico (Author)
Format: Article (Journal)
Language:English
Published: February 2024
In: Radiology
Year: 2024, Volume: 310, Issue: 2, Pages: 1-9
ISSN:1527-1315
DOI:10.1148/radiol.232044
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1148/radiol.232044
Verlag, kostenfrei, Volltext: https://pubs.rsna.org/doi/10.1148/radiol.232044
Get full text
Author Notes:Timo A. Auer, MD, Lukas Müller, MD, PhD, Daniel Schulze, MS, PhD, Melina Anhamm, Dominik Bettinger, MD, Verena Steinle, MD, Johannes Haubold, MD, David Zopfs, MD, Daniel Pinto dos Santos, MD, Michel Eisenblätter, MD, PhD, Bernhard Gebauer, MD, Roman Kloeckner, MD, Federico Collettini, MD
Description
Summary:Background - - CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR brachytherapy) has been shown to be safe and effective for patients with unresectable hepatocellular carcinoma (HCC), but studies comparing this therapy with other local-regional therapies are scarce. - - Purpose - - To compare patient outcomes of HDR brachytherapy and transarterial chemoembolization (TACE) in patients with unresectable HCC. - - Materials and Methods - - This multi-institutional retrospective study included consecutive treatment-naive adult patients with unresectable HCC who underwent either HDR brachytherapy or TACE between January 2010 and December 2022. Overall survival (OS) and progression-free survival (PFS) were compared between patients matched for clinical and tumor characteristics by propensity score matching. Not all patients who underwent TACE had PFS available; thus, a different set of patients was used for PFS and OS analysis for this treatment. Hazard ratios (HRs) were calculated from Kaplan-Meier survival curves. - - Results - - After propensity matching, 150 patients who underwent HDR brachytherapy (median age, 71 years [IQR, 63-77 years]; 117 males) and 150 patients who underwent TACE (OS analysis median age, 70 years [IQR, 63-77 years]; 119 male; PFS analysis median age, 68 years [IQR: 63-76 years]; 119 male) were analyzed. Hazard of death was higher in the TACE versus HDR brachytherapy group (HR, 4.04; P < .001). Median estimated PFS was 32.8 months (95% CI: 12.5, 58.7) in the HDR brachytherapy group and 11.6 months (95% CI: 4.9, 22.7) in the TACE group. Hazard of disease progression was higher in the TACE versus HDR brachytherapy group (HR, 2.23; P < .001). - - Conclusion - - In selected treatment-naive patients with unresectable HCC, treatment with CT-guided HDR brachytherapy led to improved OS and PFS compared with TACE.
Item Description:Online veröffentlicht: 6. Februar 2024
Gesehen am 25.02.2025
Physical Description:Online Resource
ISSN:1527-1315
DOI:10.1148/radiol.232044

Similar Items